Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Azad Engineering IPO Date, Review, Price, Allotment Details

Azad Engineering IPO Details: Azad Engineering IPO date is fixed, the IPO is to hit the market on December 20 and will close on December 22. Azad Engineering IPO to raise around ₹740 crores via IPO that comprises fresh issue of ₹240 crores and offer for sale up to ₹500 crores of ₹2 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.
Azad Engineering IPO

Azad Engineering is one of the key manufacturers of our qualified product lines supplying global original equipment manufacturers (ā€œOEMsā€) in the energy, aerospace, defense, and oil and gas industries, manufacturing highly engineered, complex, and mission and life-critical components (Source: EY Report). The company manufactures complex and highly engineered precision forged and machined components that are mission and life-critical and hence, some of their products have a ā€œzero parts per millionā€ defects requirement (Source: EY Report).


Azad Engineering’s products include 3D rotating airfoil/ blade portions of turbine engines and other critical components for (a) gas, nuclear, and thermal turbines used in industrial applications or energy generation, and (b) defense and civil aircraft and spaceships. As of September 30, 2023, the company generated a revenue of ₹1,142.92 million from the sale of airfoils/ blades for the energy industry, which comprised 72.00% of its revenue from operations. The company’s customers include global OEMs across the energy, aerospace, defense, and oil and gas industries such as General Electric, Honeywell International Inc., Mitsubishi Heavy Industries, Ltd., Siemens Energy, Eaton Aerospace, and MAN Energy Solutions SE.

Their components have been supplied to countries such as the USA, China, Europe, the Middle East, and Japan since our inception (Source: EY Report). Accordingly, They are a key link in the global supply chain for OEMs (Source: EY Report). They increased our revenue from ₹1,240.00 million in Financial Year 2020 to ₹2,516.75 million in Financial Year 2023 (CAGR of 27% between Financial Years 2020 and 2023) with an adjusted EBITDA margin of 31.61% in Financial Year 2023. They are one of the fastest growing manufacturers (in terms of revenue growth for the period between Financial Years 2020 – 2023) with one of the highest EBITDA margins among the key players for machined components for the key industries serviced by us (Source: EY Report).


Objects of the Issue

  • Funding capital expenditure of our Company;
  • Repayment/prepayment, in part or full, of certain of our borrowings availed by our Company; and
  • General corporate purposes.

Azad Engineering IPO Review (Apply or Not)

  • Apply

Brokerage Firm IPO Review

  • Canara Bank Securities: Apply
  • Nirmal Bang: Apply
  • Reliance Securities: Apply
  • Swastika Investmart: Apply
  • Ventura Securities: Apply

Azad Engineering IPO Date & Price Band Details

IPO Open:December 20, 2023
IPO Close:December 22, 2023
IPO Size:Approx ₹740 Crores
Fresh Issue:Approx ā‚¹240 Crores
Offer for Sale:Approx ā‚¹500 Crores
Face Value:₹2 Per Equity Share
IPO Price Band:₹499 to ₹524 Per Share
IPO Listing on:BSE & NSE
Retail Quota:35%
QIB Quota:50%
 NII Quota:15%
DRHP Draft Prospectus:Click Here
RHP Draft Prospectus:Click Here
Anchor Investors List:Click Here

Azad Engineering IPO Market Lot

The Azad Engineering IPO minimum market lot is 28 shares with ₹14,672 application amount. The retail investors can apply up-to 13 lots with 364 shares or ₹190,736 amount.

ApplicationLot SizeSharesAmount
Retail Minimum128₹14,672
Retail Maximum13364₹190,736
S-HNI Minimum14392₹205,408
B-HNI Minimum691,932₹1,012,368

Azad Engineering IPO Allotment & Listing Dates

The Azad Engineering IPO date is December 20 and the close date is December 22. The Azad Engineering IPO allotment will be finalized on December 26 and the IPO listing on December 28.

Anchor Investors Allotment:December 19, 2023
IPO Open Date:December 20, 2023
IPO Close Date:December 22, 2023
Basis of Allotment:December 26, 2023
Refunds:December 27, 2023
Credit to Demat Account:December 27, 2023
IPO Listing Date:December 28, 2023

You can check IPO subscription status and IPO allotment status on their respective pages.

Azad Engineering IPO Form

How to apply for the Azad Engineering IPO? You can apply for Azad Engineering IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Azad Engineering IPO in the Invest section. The other option is you can apply for Azad Engineering IPO via IPO forms downloaded via NSE and BSE. Check out the Azad Engineering forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.


Azad Engineering Company Financial Report

  ₹ in Crores
YearRevenueExpensePAT
2021₹125₹109₹11.50
2022₹199₹159₹29.46
2023₹262₹248₹8.47
2024 6M₹170₹138₹26.89

Azad Engineering IPO Valuation – FY2023

Check Azad Engineering IPO valuation details like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):₹1.79 per Equity Share
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):4.23%
Net Asset Value (NAV):₹42.30 per Equity Share

Peer Group

  • MTAR Technologies Limited
  • Paras Defence and Space Technologies Limited
  • Dynamatic Technologies Limited
  • Triveni Turbine Limited

Company Promoters

  • Rakesh Chopdar

Azad Engineering IPO Registrar

KFin Technologies Limited
Tel: +91 40 6716 2222
E-mail: azad.ipo@kfintech.com
Website: www.kfintech.com

Azad Engineering IPO Allotment Status Check

Check Azad Engineering IPO allotment status on KFintech website allotment URL. Click Here

Azad Engineering IPO Lead Managers aka Merchant Bankers

  • Axis Capital Limited
  • ICICI Securities Limited
  • SBI Capital Markets Limited
  • Anand Rathi Advisors Limited

Company Address

Azad Engineering Limited
90/C, 90/D, Phase-1, I.D.A. Jeedimetla,
Hyderabad 500 055, Telangana, India
Phone: +91 40 2309 7007
Email: cs@azad.in
Website: www.azad.in

Azad Engineering IPO FAQs

What is Azad Engineering IPO?

Azad Engineering IPO is a main-board IPO. They are going to raise ₹740 Crores via IPO. The issue is priced at ₹[.] to ₹[.] pr equity share. The IPO is to be listed on BSE & NSE.

When Azad Engineering IPO will open?

The IPO is to open on December 20, 2023 for QIB, NII, and Retail Investors.

What is Azad Engineering IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Azad Engineering IPO?

You can apply for Azad Engineering IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Azad Engineering IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Azad Engineering”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Azad Engineering IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Azad Engineering”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Azad Engineering IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Azad Engineering”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Azad Engineering IPO Size?

Azad Engineering IPO size is ₹740 crores.

What is Azad Engineering IPO Price Band?

Azad Engineering IPO Price Band is ā‚¹[.] to ₹[.].

What is the Azad Engineering IPO Allotment Date?

Azad Engineering IPO allotment date is December 26, 2023.

What is the Azad Engineering IPO Listing Date?

Azad Engineering IPO listing date is December 28, 2023. The IPO is to list on BSE and NSE.

Note: The Azad Engineering IPO price band and date are officially announced. The IPO grey market premium (Azad Engineering IPO Premium) will be added to the IPO grey market page as it will start).

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

One Response

  1. I am writing to address an issue regarding the recent AZAD Initial Public Offering (IPO) in which I participated. My name is
    Pallavi Punwatkar and my application details are
    Pan no. FSVPP4109K
    Application id. TR461711022338
    I have not received a refund for the Unallotted share in the IPO it has been 3 days since the allotment was concluded.
    I kindly request you to look into this matter and provide me with an update on the status of my refund.
    Look forward to a prompt resolution.

    Thank you for your cooperation.